Multifunctional nanoagent for thrombus-targeted fibrinolytic therapy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Thrombosis Research

Background:

• Current thrombolytic therapies using plasminogen activators (PAs) effectively dissolve blood clots but can cause dangerous bleeding.
• There is a need for safer and more targeted fibrinolytic agents to minimize side effects.

Purpose of the Study:

• To develop novel, thrombus-targeted fibrinolytic agents using nanomaterials.
• To create a nano-agent with multifunctional theranostic capabilities for improved efficacy and reduced side effects.

Main Methods:

• Synthesized a magnetofluorescent iron oxide nanoparticle conjugated to recombinant tissue plasminogen activator (tPA).
• Targeted the nanoparticles to thrombi using an activated factor XIII (FXIIIa)-sensitive peptide.
• Assessed in vitro clot binding and fibrinolytic activity, and in vivo targeting and efficacy in murine models of thrombosis and pulmonary embolism.

Main Results:

• The targeted nano-agent showed superior in vitro binding to plasma clots compared to controls.
• In vitro fibrinolytic activity was comparable to free tPA when normalized.
• The nano-agent efficiently bound intravascular thrombi in vivo and lysed pulmonary emboli with similar efficacy to free tPA.

Conclusions:

• Demonstrated the in vitro and in vivo applicability of a FXIIIa-targeted thrombolytic nano-agent for thromboembolism treatment.
• This nano-agent represents a potential advancement in targeted thrombolysis.
• Future research will focus on safety and overall efficacy of these nano-agents.